Add BrightSurf on Google Email

Osimertinib with or without chemotherapy in advanced non–small cell lung cancer with EGFR and concurrent TP53 mutations

A randomized phase 3 study found that first-line osimertinib plus chemotherapy significantly improved median progression-free survival compared to osimertinib alone in patients with advanced non–small cell lung cancer (NSCLC) and concurrent EGFR and TP53 mutations. This study provides evidence for incorporating TP53-based molecular ris...

SourceJAMA Network·JournalJAMA·DateAug 10, 2026

New study identifies behaviours influencing prescribing decisions for new medicines in neurodegenerative disease

A new pan-European study identified the psychological and contextual factors that shape decision-making among healthcare professionals. The findings provide important insights into how behaviour change frameworks could support the uptake of new treatments, with the strongest lever being to shift intention to prescribe.

SourceAston University·JournalPLOS One·TypeMeta-analysis·DateJul 28, 2026

Topline results from LiBBY trial show THC/CBD combination significantly reduces agitation for people with dementia at end of life

A Phase 2 clinical trial shows that a THC/CBD combination significantly reduces agitation in hospice-eligible people with dementia. The study, conducted across multiple US sites, achieved its primary and key secondary endpoints, demonstrating the efficacy of this treatment approach for end-of-life agitation.

Availability of generic semaglutide removes barrier to affordable diabetes care, experts predict

A new study in the Canadian Journal of Cardiology predicts that generic semaglutide will dramatically increase cost-effectiveness and health system affordability for patients with type 2 diabetes and high cardiorenal risk. The estimated annual cost of providing GLP-1RAs to all indicated patients would be $3.35 to $5.31 billion at pre-g...

SourceElsevier·JournalCanadian Journal of Cardiology·TypeData/statistical analysis·DateJul 22, 2026

Leading ADHD medications found to be equally effective in children, with one key difference

A recent study published by the University of Sydney found that dexamphetamine and methylphenidate are equally effective in treating ADHD in children, with no significant differences in symptom improvement. However, children taking dexamphetamine experienced greater weight loss compared to those taking methylphenidate.

SourceUniversity of Sydney·JournalJournal of Paediatrics and Child Health·TypeRandomized controlled/clinical trial·DateJul 15, 2026

ECOG-ACRIN ENDURANCE trial findings published in the New England Journal of Medicine provide the first randomized evidence on the optimal duration of lenalidomide maintenance for patients with newly diagnosed multiple myeloma

The ECOG-ACRIN ENDURANCE trial found that indefinite lenalidomide maintenance had no survival benefit and more toxicity compared to stopping treatment after 2 years in patients not undergoing a stem cell transplant. The study suggests that fixed duration treatment can significantly reduce healthcare costs.

SourceECOG-ACRIN Cancer Research Group·JournalNew England Journal of Medicine·DateJul 15, 2026

Obesity and dietitian societies combine to issue consensus recommendations on use of incretin drugs in obesity therapy

The European Association for the Study of Obesity, dietitian societies, and other organizations have issued a consensus statement on the use of incretin drugs in obesity therapy. Key findings include the importance of medical nutrition therapy delivered by registered dietitians to complement incretin-based therapies. The statement also...

SourceEuropean Association for the Study of Obesity·JournalThe Lancet Diabetes & Endocrinology·DateJul 8, 2026

Risk of falls, adverse events higher for older adults prescribed sedatives after hospitalization

A new study published in the Canadian Medical Association Journal found that older adults discharged from hospital with a new prescription for sedatives are at increased risk of falls, further need for acute hospital care, and death within 30 days. The study looked at over 1.86 million adults aged 66 years and older and found a 20% hig...

SourceCanadian Medical Association Journal·JournalCanadian Medical Association Journal·TypeObservational study·DateJun 29, 2026

New review highlights how modern rheumatoid arthritis treatments can protect bone health

A new review highlights advances in preventing bone loss in people with rheumatoid arthritis, showing that modern antirheumatic therapies can significantly reduce both localized erosions and generalized bone loss. Emerging imaging technologies like HR-pQCT have been found to detect subtle bone erosions earlier and more sensitively.

SourceInternational Osteoporosis Foundation·JournalCalcified Tissue International·TypeLiterature review·DateJun 10, 2026

Patient experiences with GLP-1 receptor agonists

Patients described GLP-1 RA therapy as a facilitator of lifestyle change, highlighting the need for standardized guidelines on patient education and clinical support. The quality of care was highly variable, leading to potential expectation management issues around adverse effects and long-term management.

SourceJAMA Network·JournalJAMA Network Open·DateJun 5, 2026

Senolytic drug combination delays early intervertebral disc degeneration in mice

Researchers developed a senolytic therapy using dasatinib and quercetin, which preserved disc structure and reduced inflammation, highlighting JUN signaling as a key pathway. This preclinical study provides evidence for a potential therapeutic strategy to slow disease progression in individuals with genetic susceptibility.

SourceEditorial Office of West China School of Stomatology, Sichuan University·JournalBone Research·TypeExperimental study·DateMay 25, 2026

Study: Hospital wastewater reveals drug-resistant fungus strains months before patients show symptoms

Researchers used wastewater surveillance to detect drug-resistant Candida auris strains up to five months before patients showed symptoms, opening a new frontier for hospitals. The study found higher detection rates and concentrations of the pathogen in hospital wastewater compared to community-scale treatment plants.

SourceUniversity of Nevada, Las Vegas·JournalNature Communications·DateMay 20, 2026

Targeted therapy improves mobility in children with rare bone disorder

A phase 2 clinical trial found that burosumab safely restored normal phosphate levels and improved physical function in patients with severe fibrous dysplasia. Key findings include reduced pain, fatigue, and mobility impairment, as well as significant improvements in children's mobility and independence.

SourceEditorial Office of West China School of Stomatology, Sichuan University·JournalBone Research·TypeRandomized controlled/clinical trial·DateMay 20, 2026

USC comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions

A USC-led study analyzed insurance claims data from 940 patients with ALK-positive non-small cell lung cancer to compare the effectiveness of five tyrosine kinase inhibitors. The results showed alectinib and lorlatinib as promising treatments, offering longer survival times and better treatment duration compared to other options.

SourceKeck School of Medicine of USC·JournalLung Cancer·TypeObservational study·DateMay 19, 2026

New study reveals best dosage for ADHD medications

A new study has identified the most effective dosages for five commonly used ADHD medications using data from thousands of participants. The research, published in The Lancet Psychiatry, provides a comprehensive view of dosage effects and developed an online tool to help clinicians and patients choose the right dosage.

SourceUniversity of Southampton·JournalThe Lancet Psychiatry·TypeMeta-analysis·DateMay 14, 2026

Obesity and dietician societies combine to issue consensus recommendations on use of incretin drugs in obesity therapy

The European Association for the Study of Obesity, dietitian societies, and patients' organizations have issued a new consensus statement on using incretin drugs to treat obesity. The statement highlights the importance of medical nutritional therapy (MNT) and reinforces healthy dietary patterns. It also emphasizes the need to monitor ...

Viagra could hold key to halting Peyronie’s disease

A new study published in The Journal of Sexual Medicine found that combining phosphodiesterase type 5 inhibitors with selective oestrogen receptor modulators may slow or stop disease progression when given early. This combination resulted in improved penile curvature and reduced pain during erections compared to standard care.

SourceAnglia Ruskin University·JournalThe Journal of Sexual Medicine·DateMay 14, 2026

New treatment with fewer side effects reduces breast density

A new study from Karolinska Institutet shows that low doses of endoxifen reduce breast density to the same extent as tamoxifen without causing severe side effects. The results suggest a lower dose may be sufficient for therapeutic effect while being better tolerated.

SourceKarolinska Institutet·JournalJNCI Journal of the National Cancer Institute·TypeRandomized controlled/clinical trial·DateMay 3, 2026